Annual Statements Open main menu

Indoor Harvest Corp - Quarter Report: 2023 March (Form 10-Q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023  

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from   to    

 

Commission File Number 000-55594  

 

INDOOR HARVEST CORP

 

(Exact name of registrant as specified in its charter)

 

Texas   45-5577364

(State or other jurisdiction

of incorporation or organization)

 

(IRS Employer

Identification No.)

 

7401 W. Slaughter Lane #5078

Austin, Texas

  78739
(Address of principal executive offices)   (Zip Code)

 

512-309-1776

 

(Registrant’s telephone number, including area code)

 

N/A

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

YES ☐ NO

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

 

☐ YES ☒ NO

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date 2,831,670,853 common shares issued and outstanding as of May 11, 2023.

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION F-1
     
Item 1. Financial Statements F-1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation 4
Item 3. Quantitative and Qualitative Disclosures About Market Risk 6
Item 4. Controls and Procedures 6
     
PART II - OTHER INFORMATION 7
     
Item 1. Legal Proceedings 7
Item 1A. Risk Factors 7
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 7
Item 3. Defaults Upon Senior Securities 7
Item 4. Mine Safety Disclosures 7
Item 5. Other Information 7
Item 6. Exhibits 7
SIGNATURES 8

 

2

 

 

FORWARD-LOOKING STATEMENTS

 

Except for any historical information contained herein, the matters discussed in this quarterly report on Form 10-Q contain certain “forward-looking statements’’ within the meaning of the federal securities laws. This includes statements regarding our future financial position, economic performance, results of operations, business strategy, budgets, projected costs, plans and objectives of management for future operations, and the information referred to under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

These forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “continue” or similar terminology, although not all forward-looking statements contain these words. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, you are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although we believe that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ from projections include, for example:

 

  the success or failure of management’s efforts to implement our business plan;
  our ability to fund our operating expenses;
  our ability to compete with other companies that have a similar business plan;
  the effect of changing economic conditions impacting our plan of operation; and
  our ability to meet the other risks as may be described in future filings with the Securities and Exchange Commission (the “SEC”).

 

Unless otherwise required by law, we also disclaim any obligation to update our view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this quarterly report on Form 10-Q.

 

When considering these forward-looking statements, you should keep in mind the cautionary statements in this quarterly report on Form 10-Q and in our other filings with the SEC. We cannot assure you that the forward-looking statements in this quarterly report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may prove to be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time-frame, or at all.

 

3

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

INDOOR HARVEST CORP

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   March 31,   December 31, 
   2023   2022 
   (UNAUDITED)      
ASSETS          
Current Assets:          
Cash  $7,758   $226,231 
Notes receivable, net   310,964    163,588 
Prepaid expenses and other receivable   30,658    44,085 
Total Current Assets   349,380    433,904 
           
Prepayment for acquisition-related party   145,000    145,000 
TOTAL ASSETS  $494,380   $578,904 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable and accrued liabilities  $270,197   $233,378 
Due to related party   67,000    - 
Total Current Liabilities   337,197    233,378 
           
Total Liabilities   337,197    233,378 
           
Commitments and contingencies   -    - 
           
Stockholders’ Equity          
Preferred stock: 15,000,000 authorized; $0.01 par value; Series A Convertible Preferred stock: 15,000,000 designated, 0 shares issued and outstanding   -    - 
Common stock: 10,000,000,000 authorized; $0.001 par value; 2,800,420,853 and 2,693,190,084 shares issued and outstanding, respectively   2,800,421    2,693,190 
Additional paid in capital   24,789,520    24,135,367 
Shares to be issued   -    576,000 
Accumulated deficit   (27,432,758)   (27,059,031)
Total Stockholders’ Equity   157,183    345,526 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $494,380   $578,904 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

INDOOR HARVEST CORP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
         
Revenue  $-   $- 
           
Operating Expenses          
Professional fees   306,509    433,630 
General and administrative   77,039    632,631 
Total Operating Expenses   383,548    1,066,261 
           
Loss from operations   (383,548)   (1,066,261)
           
Other Income (Expense)          
Interest income   9,821    - 
Total other income   9,821    - 
           
Loss before income taxes   (373,727)   (1,066,261)
           
Provision for income taxes   -    - 
           
Net loss  $(373,727)  $(1,066,261)
           
Comprehensive loss  $(373,727)  $(1,066,261)
           
Basic and diluted income (loss) per common share          
Basic  $(0.00)  $(0.00)
Diluted  $(0.00)  $(0.00)
           
Weighted average number of common shares outstanding          
Basic   2,759,485,810    2,578,826,597 
Diluted   2,759,485,810    2,578,826,597 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-2

 

 

INDOOR HARVEST CORP

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

For the Three months Ended March 31, 2023

 

   Number of Shares   Amount   Number of Shares   Amount  

Paid in

Capital

   to be issued  

Accumulated

Deficit

  

Stockholders’

Equity

 
   Series A Convertible                       
   Preferred Stock   Common Stock   Additional   Share       Total 
   Number of Shares   Amount   Number of Shares   Amount  

Paid in

Capital

   to be issued  

Accumulated

Deficit

  

Stockholders’

Equity

 
                                 
Balance - December 31, 2022                    -   $-    2,693,190,084   $2,693,190   $24,135,367   $   576,000   $(27,059,031)  $345,526 
                                         
Common stock and warrants issued   -    -    107,230,769    107,231    589,769    (576,000)   -    121,000 
Stock based compensation   -    -    -    -    64,384    -    -    64,384 
Net loss   -    -    -    -    -    -    (373,727)   (373,727)
Balance - March 31, 2023   -   $-    2,800,420,853   $2,800,421   $24,789,520   $-   $(27,432,758)  $157,183 

 

For the Three months Ended March 31, 2022

 

   Series A Convertible                     
   Preferred Stock   Common Stock   Additional       Total 
  

Number of

Shares

   Amount  

Number of

Shares

   Amount  

Paid in

Capital

   Accumulated Deficit   Stockholders’ Equity 
                             
Balance - December 31, 2021                    -   $-    2,575,909,930   $2,575,910   $21,210,721   $(23,695,434)  $91,197 
Balance                    -   $-    2,575,909,930   $2,575,910   $21,210,721   $(23,695,434)  $91,197 
                                    
Common stock issued for cash   -    -    12,500,000    12,500    62,500    -    75,000 
Stock based compensation   -    -    -    -    975,496    -    975,496 
Net loss   -    -    -    -    -    (1,066,261)   (1,066,261)
Balance - March 31, 2022   -   $-    2,588,409,930   $2,588,410   $22,248,717   $(24,761,695)  $75,432 
Balance   -   $-    2,588,409,930   $2,588,410   $22,248,717   $(24,761,695)  $75,432 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-3

 

 

INDOOR HARVEST CORP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
         
Cash Flows from Operating Activities:          
Net loss  $(373,727)  $(1,066,261)
Adjustments to reconcile net loss to net cash used in operating activities:          
Accrued interest - notes receivable   (4,945)   - 
Amortization debt discount - notes receivable   (4,876)   - 
Stock based compensation   64,384    975,496 
Changes in operating assets and liabilities:          
Prepaid expenses and other receivable   18,372    (7,291)
Accounts payable and accrued expenses   36,819    16,583 
Due to related party   67,000    (33,901)
Net Cash used in Operating Activities   (196,973)   (115,374)
           
Cash Flows from Investing Activities:          
Investment in short term notes   (142,500)   - 
Net Cash used in Investing Activities   (142,500)   - 
           
Cash Flows from Financing Activities:          
Proceeds from issuance of common stock and warrants   121,000    75,000 
Net Cash provided by Financing Activities   121,000    75,000 
           
Net change in cash   (218,473)   (40,374)
Cash, beginning of period   226,231    232,850 
Cash, end of period  $7,758   $192,476 
           
Supplemental Cash Flow Information          
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 
           
Non-Cash Investing and Financing Activities:          
Common stock and warrants issued from shares to be issued  $576,000   $- 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

F-4

 

 

INDOOR HARVEST CORP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2023

 

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations and Organization

 

Indoor Harvest Corp (the “Company” or “Indoor Harvest”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739, and such address is used in the interim. We are in the process of establishing new offices.

 

On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis.

 

The Company incorporates development of proprietary technology, mergers, acquisitions, strategic partnerships, and joint ventures as part of a broad integration strategy. As a platform, Indoor Harvest Corp. cultivates synergistic partnerships within related industries, providing an opportunity to be part of a more significant play, sharing intellectual capital, technology, access to new capital markets, and liquidity for owners.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the requirements of Form 10-Q and Rule 8-03 of Regulation S-X of the U.S. Securities and Exchange Commission. Accordingly, they may not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, as not all disclosures required by generally accepted accounting principles for annual financial statements may be presented.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

 

F-5

 

 

Net Loss Per Common Stock

 

Net loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive.

 

The dilutive effect of warrants and stock options subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.

 

For the three months ended March 31, 2023, and 2022, respectively, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

   2023   2022 
   Three Months Ended 
   March 31, 
   2023   2022 
   (shares)   (shares) 
Warrants   342,753,846    - 
Stock options   854,000,000    820,000,000 
Anti dilutive Securities   1,196,753,846    820,000,000 

 

Fair Value of Financial Instruments

 

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

 

The following table summarizes fair value measurements by level at March 31, 2023 and December 31, 2022, measured at fair value on a recurring basis:

 

March 31, 2023  Level 1   Level 2   Level 3   Total 
Assets:                    
Notes receivables, net  $-   $-   $310,964   $310,964 

 

December 31, 2022  Level 1   Level 2   Level 3   Total 
Assets:                    
Notes receivables, net  $-   $-   $163,588   $163,588 

 

F-6

 

 

Recent Issued Accounting Pronouncements

 

The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

 

NOTE 2 - GOING CONCERN

 

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash as of March 31, 2023, incurred losses from its operations and did not generate cash from its operation for the past two years and three months ended March 31, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

 

NOTE 3 – NOTES RECEIVABLE

 

During the three months ended March 31, 2023, the Company granted loans of $142,500. As March 31, 2023 and December 31, 2022, the following secured promissory notes the Company utilized in the Membership Interest and Stock Purchase Agreement dated April 28, 2023 (see Note 7 – Subsequent Events):

 

   Principal   Maturity  Amended Maturity  Interest   Original Issue   March 31.   December 31. 
Issuance date  Amount   Date  date  Rate   Discount   2023   2022 
7/27/2022  $40,000   5/27/2023  10/27/2023   8%  $4,001   $44,001   $42,668 
8/10/2022  $20,000   6/10/2023  10/10/2023   8%  $1,867    21,867    21,334 
9/15/2022  $40,000   1/15/2023  10/15/2023   8%  $3,467    43,467    41,068 
11/1/2022  $25,000   3/1/2023  10/1/2023   8%  $1,835    26,835    25,667 
11/8/2022  $20,000   3/8/2023  10/8/2023   8%  $1,468    21,468    20,534 
12/8/2022  $15,000   4/8/2023  10/8/2023   8%  $1,001    16,001    15,401 
1/5/2023  $27,500   7/5/2023  10/5/2023   8%  $1,650    29,150    - 
1/20/2023  $50,000   7/20/2023  10/20/2023   8%  $3,000    53,000    - 
2/28/2023  $65,000   9/28/2023  -   8%  $3,036    68,036    - 
Total notes receivable                       $323,825   $166,672 
Less: unearned OID                        (12,861)   (3,084)
Current-portion                        (310,964)   (163,588)
Long-term portion                       $-   $- 

 

F-7

 

 

The notes are secured by an interest in real property as set nine security agreements between the Company and borrower. During the three months ended March 31, 2023, the Company recognized interest income of $9,821. The Company’s management did not recognize any estimated credit loss for the notes; however, the management closely monitors the liquidity of the debtors for changes in circumstances that may affect the carrying value of these notes. The notes are considered level 3 financial instruments; however, as a result of the short terms to maturity, their amortized costs approximate their fair values.

 

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities on March 31, 2023, and December 31, 2022, are as follows:

 

   March 31,   December 31, 
   2023   2022 
Accounts payable  $176,393   $139,603 
Credit card   6,901    7,877 
Accrued expenses   86,903    82,715 
Accrued management fee   -    3,183 
Accounts payable and accrued liabilities  $270,197   $233,378 

 

NOTE 5 - STOCKHOLDERS’ EQUITY

 

Common stock

 

On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 shares of the Company’s common stock, at price of $0.0065 per share and an equal number of Warrants with an exercise price of $0.013 for total consideration to the Company of $800,000. On August 12, 2022, and November 9, 2022, the number shares was increased to 153,846,154 (for total consideration to the Company of $1,000,000) and 200,000,000 shares (for total consideration to the Company of $1,300,000) an equal number of Warrants with an exercise price of $0.013, respectively. On January1, 2023, the number of Warrants increased by one share for two Warrants.

 

During the three months ended March 31, 2022, the Company issued 12,500,000 shares of common stock at $0.006 per share for cash of $75,000. Upon the change of the share price for the private placement, an additional 2,500,000 common shares were issued during the three months ended June 30, 2022.

 

During the three months ended March 31, 2023, the Company issued 107,230,769 shares of common stock for private placements at $0.0065 per share for proceeds of $697,000.

 

As of March 31, 2023, and December 31, 2022, there were 2,800,420,853 and 2,693,190,084 shares of Common Stock issued and outstanding, respectively.

 

Shares to be issued

 

During the year ended December 31, 2022, in connection with the mentioned private placement offering on August 12, 2022, the Company received $576,000 in cash proceeds. During the three months ended March 31, 2023, the Company issued restricted common shares and warrants pursuant to the closing of the August 2022 Offering totaling 88,615,385 restricted common shares and 177,230,770 warrants.

 

Additional paid in capital

 

Stock Options

 

During the three months ended March 31, 2023, the Company recognized stock option expense of $64,384, of which $48,188 was to related parties, and as of March 31, 2023, $32,393 remains unamortized, of which $0 is with related parties. The intrinsic value of the 854,000,000 options outstanding as of March 31, 2023, was $0.

 

F-8

 

 

The following is a summary of stock option activity during the three months ended March 31, 2023:

 

   Options Outstanding   Weighted Average 
   Number of   Weighted Average   Remaining life 
   Options   Exercise Price   (years) 
             
Outstanding, December 31, 2022   854,000,000   $0.012    8.56 
Granted   -    -    - 
Exercised   -    -    - 
Forfeited/canceled   -    -    - 
Outstanding, March 31, 2023   854,000,000   $0.012    8.35 
Exercisable options, March 31, 2023   847,000,000   $0.012    8.35 

 

Warrants

 

As part of an August 12, 2022 private placement and amendment dated January 1, 2023, the Company granted warrants to purchase a common share for each common share purchased. The warrants issued have an exercise price of $0.013 per warrant and expire five years from the date of grant. During the three months ended March 31, 2023, the Company granted 226,307,692 warrants, respectively.

 

Valuation

 

The Company determined the warrants to be an equity instrument, to be valued as a level 3 fair value financial instrument valued on a non-recurring basis and utilized the Black-Scholes valuation model. The Company utilized the following assumptions:

 

   Three Months ended  
   March 31, 
   2023 
Term   5.00 years 
Expected average volatility   188% - 190%
Expected dividend yield   - 
Risk-free interest rate   3.63% - 4.22%

 

The following is a summary of warrant activity during the three months ended March 31, 2023:

 

   Warrants Outstanding   Weighted Average 
   Number of   Weighted Average   Remaining life 
   Warrants   Exercise Price   (years) 
Outstanding, December 31, 2022   116,446,154   $0.010    4.38 
Granted   226,307,692    0.013    5.00 
Exercised   -    -      
Forfeited/canceled   -    -      
Outstanding, March 31, 2023               
    342,753,846   $0.013    4.85 

 

The intrinsic value of the warrant outstanding as of March 31, 2023, is $0.

 

F-9

 

 

NOTE 6 - RELATED PARTY TRANSACTIONS

 

During the three months ended March 31, 2023, and 2022, the Company paid consulting fees of $157,500 and $31,500, communication and technology services of $43,500 and $22,194, late charge of $0 and $508 to an entity under common control of the Company, respectively.

 

During the three months ended March 31, 2023, and 2022, the Company recognized stock option expense for related parties of $48,188 and $975,496, respectively. The stock option-based compensation recognized in additional paid-in-capital.

 

As of March 31, 2023, and December 31, 2022, the Company was obligated to a related party, for an unsecured, non-interest-bearing demand with balance of $67,000 and $0, respectively.

 

NOTE 7 - SUBSEQUENT EVENTS

 

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure, except as follows:

 

On April 28, 2023, The Company entered into a Membership Interest and Stock Purchase Agreement with an individual (Seller) to buy 100% of the issued and outstanding Membership Interests of the Opportunity Development Group, LLC and its subsidiary (369 Hemp, Inc. a Nevada corporation). The Agreement provides that, subject to the terms and conditions set forth therein, the Company will indirectly, wholly-own the subsidiary by acquiring minor’s Membership Interest in the subsidiary and Seller’s Membership Interests.

 

Under the terms of the Agreement, the aggregate purchase price of $1,675,000 consists of the following consideration: (i) a cash consideration payment at closing consisting of eight hundred thousand dollars ($800,000) to each of Seller and minor shareholder in accordance with their Pro Rata Portion, less the $313,089 due and owing to the Company in connection with certain nine separate promissory notes issued by Opportunity Development Group, LLC to the Company between July 27, 2022 and February 28, 2023, and (ii) a stock consideration payment at closing consisting of one hundred twenty-five million shares (125,000,000) of Indoor Harvest’s common stock, $0.001 par value per share.

 

369 Hemp, Inc. is a company engaged in the business of manufacturing and distributing hemp cigarettes. Key commercial customers include Green Hemp Co., VGO Market, Xtreme Wholesale and other regional wholesalers, 369 Hemp Inc. has 8 employees and was founded in early 2019 and is based in Mocksville, North Carolina.

 

On April 30, 2023, Indoor Harvest Corp. (“Indoor Harvest”) entered into a Membership Interest and Stock Purchase Agreement with Metabiogenix USA, LLC, a Texas limited liability company (the “Company”), Metabiogenics, Ltd., S.A. de C.V. and other individual members of the Company, (each a “Seller” and collectively the “Sellers”), and Sellers owns all of the issued and outstanding membership interests (the “Membership Interests”) of the Company. The Agreement provides that, subject to the terms and conditions set forth therein, Indoor Harvest will acquire a sixty percent (60%) controlling interest in the Company by acquiring a portion of Sellers’ Membership Interests in the Company.

 

Under the terms of the Agreement, the aggregate purchase price of $2,500,000 consists of the following consideration: (i) a cash consideration payment of four hundred thousand dollars ($400,000) to each Seller in accordance with their Pro Rata Portion, less one hundred thousand dollars ($100,000) previously paid to Sellers, with fifty thousand dollars ($50,000) to paid at closing, and the remaining cash consideration of two hundred fifty thousand ($250,000) to be paid to Sellers in accordance with the Pro Rata Portion in five monthly installments with the first installment to be paid on or before June 1, 2023 and each remaining monthly installment to be paid on the first day of each following month until all funds are paid in full; and (ii) a stock consideration payment at closing consisting of three hundred million shares (300,000,000) of Indoor Harvest’s common stock, $0.001 par value per share. In addition, the Sellers are entitled to bonus consideration, in the form of warrants to purchase an aggregate of 150,000,000 shares of Common Stock, upon the Company achieving certain revenue related milestones as set forth in the Agreement.

 

Metabiogenix USA, LLC, is the officially licensed distributor of Metabiox® across the Western Hemisphere (North, South, and Central America), and Spain. Metabiox® was developed by the Japanese Medical Institute and is produced in Japan.

 

On April 12,2023, the Company’s board of directors approved to issue a convertible note of $312,500 with 20% discount, at rate of 6% per annum and maturity date shall be ninety days after issuance of note (April 12, 2023). The Company’s board of directors also deems it in the best interest of the Company to issue to investor 31,250,000 shares of common stock and a warrant for 31,250,000 shares of common stock with exercise price of $0.01 per share subject to adjustment and for term of five years. Pursuant to the agreement, the Company obtained $180,500 in cash after distribution attorney and brokers fees.

 

On April 30, 2023, pursuant to private placement dated January 01, 2023, the Company entered into a subscription agreement with an individual investor for issuance of 10,000,000 shares of common stock at $0.0065 per share and a warrant for 20,000,000 shares of common stock.

 

F-10

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

Results of Operations

 

The following tables presents our operating results for the three months ended March 31, 2023 compared to March 31, 2022:

 

Three months ended March 31, 2023 compared to three months ended March 31, 2022

 

   Three Months Ended         
   March 31,         
   2023   2022   Change   % 
Revenue  $-   $-   $-    - 
Operating expenses                    
Depreciation and amortization expense   -    -           
Professional fees   306,509    433,630    (127,121)   (29)%
General and administrative expenses   77,039    632,631    (555,592)   (89)%
Total operating expenses   383,548    1,066,261    (682,713)   (64)%
Loss from operations   (383,548)   (1,066,261)   682,713    64%
Other expense                    
Other income (expense)        -    -      
Interest income   9,821    -    9,821    100%
Interest expense   -    -    -    - 
Total other income (expense)   9,821    -    9,821    100%
                     
Net income (loss)  $(373,727)  $(1,066,261)  $672,892    64%

 

Revenues

 

During the three months ended March 31, 2023 and 2022, the Company generated no revenue.

 

Operating Expenses

 

Total operating expenses for the three months ended March 31, 2023 and 2022 were $383,548 and $1,066,261, respectively, for an aggregate decrease of $682,713 or 64%. The aggregate decrease was primarily driven by a decrease in general and administrative expenses associated with executive stock options compensation.

 

Other Income (Expense)

 

Total other income (expense) for the three months ended March 31, 2023 and 2022 were $9,821 and $0, respectively. The increase in other income is primarily related to Interest Income on the Notes Receivable.

 

4

 

 

Net Loss

 

As a result of the factors discussed above, net income for the three months ended March 31, 2023 and 2022 was a loss of $373,727 and $1,066,261, respectively, for an aggregate decrease of $672,892, or 64% primarily driven by a decrease in general and administrative expenses associated with executive stock options compensation.

 

Liquidity and Capital Resources

 

The following table provides selected financial data about our Company as of March 31, 2023 and December 31, 2022, respectively.

 

Working Capital

 

   March 31,
2023
   December 31,
2022
   Change   % 
Current assets  $349,380   $433,904   $(84,524)   (19)%
Current liabilities  $337,197   $233,378   $103,819    44%
Working capital (deficiency)  $12,183   $200,526   $(188,343)   (94)%

 

Cash Flows

 

   Three Months Ended         
   March 31         
   2023   2022   Change   % 
Cash used in operating activities  $(196,973)  $(115,374)  $(81,599)   71%
Cash used in investing activities  $(142,500)   -    (142,500)   100%
Cash provided by financing activities  $121,000   $75,000   $46,000    61%
Net change in cash during period  $(218,473)  $(40,374)  $(178,099)   (441)%

 

As of March 31, 2023, our Company’s cash balance was $7,758 and total assets were $494,380. As of December 31, 2022, our Company’s cash balance was $226,231 and total assets were $578,904.

 

As of March 31, 2023, our Company had total liabilities of $337,197 compared with total liabilities of $233,378 as of December 31, 2022.

 

As of March 31, 2023, our Company had working capital of $12,183 compared with working capital of $200,526 as of December 31, 2022. The decrease in working capital was primarily attributed to payment for consulting and vendor services, payments on accounts payables and accrued liabilities, and investing activities related to acquisitions and business development initiatives.

 

Cash Flow used in Operating Activities

 

Net cash used in operating activities for the three months ended March 31, 2023 and 2022 were $196,973 and $115,374 respectively, for an increase of $81,599. The increase in net cash used in operating activities is primarily related to payment for consulting and vendor services, payments on accounts payables and accrued liabilities, merger and acquisition related costs, and business development.

 

Cash Flow used in Investing Activities

 

For the three months ended March 31, 2023 and 2022, the Company invested $142,500 and $0 respectively, for an increase of $142,500. The increase in investing activities is related to acquisitions and business development initiatives.

 

Cash Flow provided by Financing Activities

 

Net cash provided by financing activities for the three months ended March 31, 2023 and 2022 were $121,000 and $75,000, respectively. During the nine months ended March 31, 2023, the increase in cash from financing activities was the result of the Company’s receipt of cash proceeds from private placement offerings.

 

5

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company”, we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer, Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

The Company’s management, consisting solely of the Company’s Chief Executive Officer, Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer has concluded that, as of March 31, 2023, the Company’s disclosure controls and procedures were not effective because of the following internal control over financial reporting deficiencies:

 

● We currently have an insufficient complement of personnel with the necessary accounting expertise and an inadequate supervisory review structure with respect to the requirements and application of US GAAP and SEC disclosure requirements.

 

● We currently have insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements.

 

● We currently lack a formal process and timeline for closing the books and records at the end of each reporting period and such weaknesses restrict the Company’s ability to timely gather, analyze and report information relative to the financial statements.

 

● Our Company’s management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist.

 

We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

 

Changes in Internal Controls

 

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

6

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time we may become involved in various legal proceedings that arise in the ordinary course of business. We are not currently a party to any material legal proceeding.

 

Item 1A. Risk Factors

 

As a “smaller reporting company”, we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 shares of the Company’s common stock, at price of $0.0065 per share and an equal number of Warrants with an exercise price of $0.013 for total consideration to the Company of $800,000. On August 12, 2022, and November 9, 2022, the number shares was increased to 153,846,154 (for total consideration to the Company of $1,000,000) and 200,000,000 shares (for total consideration to the Company of $1,300,000) an equal number of Warrants with an exercise price of $0.013, respectively. On January 1, 2023, the number of Warrants increased by one share for two Warrants.

 

During the three months ended March 31, 2023, the Company issued 107,230,769 shares of common stock for private placements at $0.0065 per share for proceeds of $121,000.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

(a) Not applicable.

 

(b) Not applicable.

 

Item 6. Exhibits

 

The following exhibits are included as part of this report:

 

       

INCORPORATED BY

REFERENCE

Exhibit   Description   Form   Exhibit   Filing Date
                 
(31)   Rule 13a-14(a)/15d-14(a) Certifications            
*   Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer            
*   Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer            
                 
(32)   Section 1350 Certifications            
*   Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer and Principal Financial Officer            
                 
(101)   Interactive Data Files            
*   Inline XBRL Instance Document            
*   Inline XBRL Taxonomy Extension Schema Document            
*   Inline XBRL Taxonomy Extension Calculation Linkbase Document            
*   Inline XBRL Taxonomy Extension Definition Linkbase Document            
*   Inline XBRL Taxonomy Extension Label Linkbase Document            
*   Inline XBRL Taxonomy Extension Presentation Linkbase Document            
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)            
                 
  Management Contract or Compensation Plan            

 

* Filed herewith. In addition, in accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

 

7

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INDOOR HARVEST CORP.
  (Registrant)
   
Dated: May 22, 2023 /s/ Leslie Bocskor
  Leslie Bocskor
  Chief Executive Officer, Chief Financial Officer
  (Principal Executive Officer)(Principal Financial Officer)

 

8